Inscrição na biblioteca: Guest
Critical Reviews™ in Immunology

Publicou 6 edições por ano

ISSN Imprimir: 1040-8401

ISSN On-line: 2162-6472

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.3 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.6 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00079 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.24 SJR: 0.429 SNIP: 0.287 CiteScore™:: 2.7 H-Index: 81

Indexed in

HER-2/neu Oncogenic Protein: Issues in Vaccine Development

Volume 18, Edição 1-2, 1998, pp. 37-45
DOI: 10.1615/CritRevImmunol.v18.i1-2.50
Get accessGet access

RESUMO

Vaccine studies using whole tumor cells or heterogeneous mixtures of tumor antigens provide intriguing evidence that cancer vaccines might be effective. Now it is possible to test vaccines composed of well-characterized proteins and peptides. Testing vaccine formulations composed of known and defined antigens will allow a more precise determination as to why vaccines work when they work, and why they do not work when they fail. The demonstration that human malignancy is immunogenic and the definition of human tumor antigens has set the stage for a new generation of cancer vaccines directly targeting immunogenic cancer-related peptides and proteins. Many newly defined tumor antigens are self proteins. As an example, screening existent immunity in human melanoma has identified responses to nonmutated self proteins: MAGE, MART, gplOO, and tyrosinase. Tolerance to self antigens now emerges as a possible mechanism of tumor immune escape. A new puzzle has emerged for tumor immunologists to solve; how to harness immunity to "self" tumor antigens for cancer therapeutics.

CITADO POR
  1. Curigliano Giuseppe, Spitaleri Gianluca, Dettori Manuela, Locatelli Marzia, Scarano Eloise, Goldhirsch Aron, Vaccine immunotherapy in breast cancer treatment: promising, but still early, Expert Review of Anticancer Therapy, 7, 9, 2007. Crossref

  2. Disis Mary L., West Howard L., Schiffman Kathy, Cancer Vaccines for the Treatment and Prevention of Non–Small-Cell Lung Cancer, Clinical Lung Cancer, 1, 4, 2000. Crossref

  3. Knutson K. L., Disis M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy, Cancer Immunology, Immunotherapy, 54, 8, 2005. Crossref

  4. Ben-Yedidia Tamar, Arnon Ruth, Epitope-based vaccine against influenza, Expert Review of Vaccines, 6, 6, 2007. Crossref

  5. Disis Mary L, Schiffman Kathy, Salazar Lupe G, Almand Bond, Knutson Keith L, , 21, 2003. Crossref

  6. Schiffman Kathy, Disis Mary L., HER2/neu Peptide-Based Vaccines, with GM-CSF as an Adjuvant, in Patients with Advanced-Stage HER2/neu–Expressing Cancers, Clinical Lung Cancer, 2, 1, 2000. Crossref

  7. LATTIME EDMUND C., EISENLOHR LAURENCE C., GOMELLA LEONARD G., MASTRANGELO MICHAEL J., In Situ Immune Modulation Using Recombinant Vaccinia Virus Vectors: Preclinical Studies to Clinical Implementation, in Gene Therapy of Cancer, 2002. Crossref

  8. Knutson Keith L., Disis Mary L., Expansion of HER2/neu-Specific T Cells Ex Vivo Following Immunization with a HER2/neu Peptide-Based Vaccine, Clinical Breast Cancer, 2, 1, 2001. Crossref

  9. Sharma Anupama, Czerniecki Brian J, Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells, Expert Review of Clinical Pharmacology, 2, 5, 2009. Crossref

  10. DeLuca D. S., Blasczyk R., The immunoinformatics of cancer immunotherapy, Tissue Antigens, 70, 4, 2007. Crossref

  11. Hueman Matthew T., Stojadinovic Alexander, Storrer Catherine E., Dehqanzada Zia A., Gurney Jennifer M., Shriver Craig D., Ponniah Sathibalan, Peoples George E., Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine, Cancer Immunology, Immunotherapy, 56, 2, 2006. Crossref

  12. Gordan J.D., Vonderheide R.H., Universal tumor antigens as targets for immunotherapy, Cytotherapy, 4, 4, 2002. Crossref

  13. Herlyn Dorothee, Birebent Brigitte, Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development, Annals of Medicine, 31, 1, 1999. Crossref

  14. Smith Heath A., McNeel Douglas G., The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy, Clinical and Developmental Immunology, 2010, 2010. Crossref

  15. Klapper Leah N., Kirschbaum Mark H., Seta Michael, Yarden Yosef, , 77, 1999. Crossref

  16. Eccles Suzanne, c-erbB-2 as a target for immunotherapy, Expert Opinion on Investigational Drugs, 7, 11, 1998. Crossref

  17. HANSKI CHRISTOPH, ITZKOWITZ STEVEN H., Translating the Knowledge of Molecular Alterations That Occur during Colon Carcinogenesis into Clinically Relevant Solutions, Annals of the New York Academy of Sciences, 910, 1, 2006. Crossref

  18. Muller Claude P., Putz Mike M., Peptide Vaccines, in Topley & Wilson's Microbiology and Microbial Infections, 2010. Crossref

  19. Knutson Keith L., Schiffman Kathy, Disis Mary L., Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients, Journal of Clinical Investigation, 107, 4, 2001. Crossref

  20. Miyamoto Hiroshi, Kubota Yoshinobu, Noguchi Sumio, Takase Kazunori, Matsuzaki Junichi, Moriyama Masatoshi, Takebayashi Shigeo, Kitamura Hitoshi, Hosaka Masahiko, c-erbb-2 gene amplification as a prognostic marker in human bladder cancer, Urology, 55, 5, 2000. Crossref

  21. Pietersz Geoffrey A, Li Wenjun, Apostolopoulos Vasso, A 16-mer peptide (RQIKIWFQNRRMKWKK) from antennapedia preferentially targets the Class I pathway, Vaccine, 19, 11-12, 2001. Crossref

  22. Mittendorf Elizabeth A, Holmes Jarrod P, Murray James L, von Hofe Eric, Peoples George E, CD4+T cells in antitumor immunity: utility of an Ii-Key HER2/neu hybrid peptide vaccine (AE37), Expert Opinion on Biological Therapy, 9, 1, 2009. Crossref

  23. Kiessling Rolf, Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., Seliger B., , 85, 2002. Crossref

  24. Havranek E.G., Whelan M.A., Greenhalgh R., Dalgleish A.G., Pandha H., Advances in prostate cancer immunotherapy, Surgical Oncology, 11, 1-2, 2002. Crossref

  25. Cruz Jay S.Dela, Lau Suk Ying, Ramirez Ernesto M, Giovanni Carla De, Forni Guido, Morrison Sherie L, Penichet Manuel L, Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody–cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice, Vaccine, 21, 13-14, 2003. Crossref

  26. Salazar Lupe G., Coveler Andrew L., Swensen Ron E., Gooley Theodore A., Goodell Vivian, Schiffman Kathy, Disis Mary L., Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers, Clinical Immunology, 125, 3, 2007. Crossref

  27. Hudson Amy R., Smoller Bruce R., IMMUNOHISTOCHEMISTRY IN DIAGNOSTIC DERMATOPATHOLOGY, Dermatologic Clinics, 17, 3, 1999. Crossref

  28. Fioretti Daniela, Iurescia Sandra, Fazio Vito Michele, Rinaldi Monica, DNA Vaccines: Developing New Strategies against Cancer, Journal of Biomedicine and Biotechnology, 2010, 2010. Crossref

  29. Salgaller Michael L, The development of immunotherapies for non-small cell lung cancer, Expert Opinion on Biological Therapy, 2, 3, 2002. Crossref

  30. Pejawar-Gaddy Sharmila, Finn Olivera J., Cancer vaccines: Accomplishments and challenges, Critical Reviews in Oncology/Hematology, 67, 2, 2008. Crossref

  31. Vlahopoulos Spiros, Gritzapis Angelo D., Perez Sonia A., Cacoullos Nike, Papamichail Michail, Baxevanis Constantine N., Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin, Vaccine, 27, 34, 2009. Crossref

  32. Kao Henry , Marto Jarrod A. , Hoffmann Thomas K. , Shabanowitz Jeffrey , Finkelstein Sydney D. , Whiteside Theresa L. , Hunt Donald F. , Finn Olivera J. , Identification of Cyclin B1 as a Shared Human Epithelial Tumor-Associated Antigen Recognized by T Cells , Journal of Experimental Medicine, 194, 9, 2001. Crossref

  33. Kono Koji, Takahashi Akihiro, Amemiya Hideki, Ichihara Fumiko, Sugai Hidemitsu, Iizuka Hidehiko, Fujii Hideki, Matsumoto Yoshiro, Frequencies of HER-2/neu overexpression relating to HLA haplotype in patients with gastric cancer, International Journal of Cancer, 98, 2, 2002. Crossref

  34. Bell Richard, Duration of therapy in metastatic breast cancer: management using Herceptin®, Anti-Cancer Drugs, 12, 7, 2001. Crossref

  35. Villunger Andreas, Strasser Andreas, The great escape: Is immune evasion required for tumor progression?, Nature Medicine, 5, 8, 1999. Crossref

  36. Vidovic Damir, Graddis Thomas, Chen Feng, Slagle Paul, Diegel Michael, Stepan Lara, Laus Reiner, Antitumor vaccination with HER-2-derived recombinant antigens, International Journal of Cancer, 102, 6, 2002. Crossref

  37. Graziano Daniel F., Finn Olivera J., Tumor Antigens and Tumor Antigen Discovery, in Tumor Immunology and Cancer Vaccines, 123, 2005. Crossref

  38. Nicchitta Christopher V., gp96 and Tumor Immunity, in Cell Stress Proteins, 7, 2007. Crossref

  39. Meyer zum Büschenfelde Christian, Metzger Jochen, Hermann Christine, Nicklisch Nicole, Peschel Christian, Bernhard Helga, The Generation of Both T Killer and Th Cell Clones Specific for the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells, The Journal of Immunology, 167, 3, 2001. Crossref

  40. Meyer zum Büschenfelde Christian, Nicklisch Nicole, Rose-John Stefan, Peschel Christian, Bernhard Helga, Generation of Tumor-Reactive CTL Against the Tumor-Associated Antigen HER2 Using Retrovirally Transduced Dendritic Cells Derived from CD34+Hemopoietic Progenitor Cells, The Journal of Immunology, 165, 7, 2000. Crossref

  41. Ying Han, Zeng Gang, Black Keith L., Innovative Cancer Vaccine Strategies Based on the Identification of Tumour-Associated Antigens, BioDrugs, 15, 12, 2001. Crossref

  42. Berger Carmen M., Knutson Keith L., Salazar Lupe G., Kathy Schiffman PA-C, Disis Mary L., Peptide-Based Vaccines, in Handbook of Cancer Vaccines, 2004. Crossref

  43. McNeel Douglas G., Schiffman Kathy, Disis Mary L., Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 93, 8, 1999. Crossref

  44. McNeel Douglas G., Schiffman Kathy, Disis Mary L., Immunization With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor as a Vaccine Adjuvant Elicits Both a Cellular and Humoral Response to Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor, Blood, 93, 8, 1999. Crossref

  45. Ghahremanifard Parisa, Afzali Farzaneh, Rostami Amin, Nayeri Zahra, Bambai Bijan, Minuchehr Zarrin, Designing a Novel Multi-epitope T Vaccine for “Targeting Protein for Xklp-2” (TPX2) in Hepatocellular Carcinoma Based on Immunoinformatics Approach, International Journal of Peptide Research and Therapeutics, 26, 2, 2020. Crossref

  46. Disis Mary L., Rinn Kristine, Knutson Keith L., Davis Donna, Caron Dania, dela Rosa Corazon, Schiffman Kathy, Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu–overexpressing cancers, Blood, 99, 8, 2002. Crossref

  47. Baxevanis Constantin N, Voutsas Ioannis F, Gritzapis Angelos D, Perez Sonia A, Papamichail Michael, HER-2/neu as a target for cancer vaccines, Immunotherapy, 2, 2, 2010. Crossref

  48. Janikashvili Nona, Larmonier Nicolas, Katsanis Emmanuel, Personalized dendritic cell-based tumor immunotherapy, Immunotherapy, 2, 1, 2010. Crossref

  49. Disis Mary L., Gooley Theodore A., Rinn Kristine, Davis Donna, Piepkorn Michael, Cheever Martin A., Knutson Keith L., Schiffman Kathy, Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines, Journal of Clinical Oncology, 20, 11, 2002. Crossref

  50. Smorlesi A, Papalini F, Orlando F, Donnini A, Re F, Provinciali M, Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma, Gene Therapy, 12, 17, 2005. Crossref

  51. Lane Cecilia, Leitch Jaina, Tan Xiaohua, Hadjati Jamishid, Bramson Jonathan L., Wan Yonghong, Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin, Cancer Research, 64, 4, 2004. Crossref

  52. Houghton Raymond L., Dillon Davin C., Molesh David A., Zehentner Barbara K., Xu Jiangchun, Jiang John, Schmidt Cheryl, Frudakis Anthony, Repasky Elizabeth, Filho Aristides Maltez, Nolasco Marcos, Badaro Roberto, Zhang Xinqun, Roche Patrick C., Persing David H., Reed Steven G., Transcriptional Complementarity in Breast Cancer: Application to Detection of Circulating Tumor Cells, Molecular Diagnosis, 6, 2, 2001. Crossref

Próximos artigos

Identification of a novel five-gene prognostic model for laryngeal cancer associated with mitophagy using integrated bioinformatics analysis and experimental verification Dong Song, Lun Dong, Mei Wang, Xiaoping Gao Function of steroid receptor coactivators (SRCs) in T cells and cancers: Implications for cancer immunotherapy Wencan Zhang, Xu Cao, Hongmin Wu, Xiancai Zhong, Yun Shi, Zuoming Sun Electroacupuncture Alleviates Ischemic Stroke by Activating the mTOR/SREBP1 Pathway Jiawang Lang, Jianchang Luo, Luodan Wang, Wenbin Xu, Jie Jia, Zhipeng Zhao, Boxu Lang KIAA1429 induces the m6A modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cell via JAK/STAT3 pathway Di Xu, Ziming Wang, Fajiu Li Effect of p-estrogen receptor at serine on its function and breast growth Yuan Liang, Junhui Qin, Tiancheng Ma, Tong Yang, Zhenyu Ke, Ruian Wang Mechanistic Insights into Tanshinone IIA in the Amelioration of Post-Thyroidectomy Hypoparathyroidism Xiaoyu Qian, Lin Li, Liang Chen, Chao Shen, Jian Tang MiRNA let-7d-5p alleviates inflammatory responses by targeting Map3k1 and inactivating ERK/p38 MAPK signaling in microglia Fan Fang, Cheng Chen Role of Natural Killer Cells as Cell-Based Immunotherapy in Oral Tumor Eradication and Differentiation Both In Vivo and In Vitro Kawaljit Kaur, Anahid Jewett The Current and Future States of Natural Killer Cell-Based Immunotherapy in Hepatocellular Carcinoma Tu Nguyen, Po-Chun Chen, Janet Pham, Kawaljit Kaur, Steven Raman, Anahid Jewett, Jason Chiang Phillygenin alleviated arthritis through the inhibition of NLRP3 inflammasome and Ferroptosis by AMPK Jianghui Wang, Shufang Ni, Kai Zheng, Yan Zhao, peihong zhang, Hong Chang The value of systemic immune-inflammation index and T cell subsets in the severity and prognosis of sepsis Hao Zhou Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach Muhammad Imran Qadir, Bilal Ahmed, Nadir Hussain Serum interleukin 6 and ferritin levels are the independent risk factors for pneumonia in elderly patients Hao Yuan, Jing Tian, Lu Wen Exploration of diagnostic markers associated with inflammation in chronic kidney disease (CKD) based on WGCNA and machine learning Qianjia Wu, Yang Yang, Chongze Lin Clinical significance of serum CTRP3 level in the prediction of cardiac dysfunction and intestinal mucosal barrier dysfunction in patients with severe acute pancreatitis Qiang Shao, Lin Sun The protective effect and mechanism of mild hypothermia on pig lung injury after cardiopulmonary resuscitation Jinlin Ren, Fangfang Zhu, Dongdong Sang, Mulin Cong, Shujuan Jiang Exploring mechanism of Zilongjin in treating lung adenocarcinoma based on network pharmacology combined with experimental verification Kang Zhang, Xiaoqun Chen Gastric Cancer Immune Subtypes and Prognostic Modeling: Insights from Aging-Related Genes Analysis Jian Shen, Minzhe Li Effects of different doses of dexmedetomidine on the prevention of postoperative sleep disturbance and serum neurotransmitter level in patients under general anesthesia Huifei Lu, Fei He, Ying Huang, Zhongliang Wei Identification of key ubiquitination-related genes and their associated with immune infiltration in osteoarthritis based on mRNA-miRNA network Dalu Yuan, Hailiang Shen, Lina Bai, Menglin Li, Qiujie Ye Diagnostic and Prognostic value of peripheral neutrophil CD64 index in elderly patients with community-acquired pneumonia Yan Li, Jing Zhang, Suhang Wang, Jie Cao Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of Head and Neck Squamous Cell Carcinoma Rongjin Zhou, Junguo Wang Downregulation of miR-503-5p promotes the development of pancreatic cancer via targeting cyclin E2 Fei Li, Ying-pei Ling, Pan Wang, Shi-cheng Gu, Hao Jiang, Jie Zhu
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain